Crispr Therapeutics AG (CRSP)
NASDAQ:CRSP
Holding CRSP?
Track your performance easily

Crispr Therapeutics AG (CRSP) Financial Statements

8,442 Followers

Crispr Therapeutics AG Financial Overview

Crispr Therapeutics AG's market cap is currently ―. The company's EPS TTM is $-2.823; its P/E ratio is -18.28; Crispr Therapeutics AG is scheduled to report earnings on February 18, 2025, and the estimated EPS forecast is $-1.26. See an overview of income statement, balance sheet, and cash flow financials.
Sep 24Jun 24Mar 24Dec 23Sep 23
Income Statement-
Total Revenue$ 602.00K$ 517.00K$ 504.00K$ 201.21M-
Gross Profit$ 602.00K$ 517.00K$ 504.00K$ 137.81M$ -23.42M
EBIT$ -85.07M$ -125.12M$ -68.90M$ 69.58M$ -111.74M
EBITDA$ -80.33M$ -120.28M$ -64.07M$ 74.48M$ -106.81M
Net Income Common Stockholders$ -85.94M$ -126.41M$ -116.59M$ 89.35M$ -112.15M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 1.94B$ 2.00B$ 2.11B$ 1.69B$ 1.74B
Total Assets$ 2.26B$ 2.34B$ 2.44B$ 2.23B$ 2.09B
Total Debt$ 227.54M$ 231.30M$ 234.93M$ 238.63M$ 241.59M
Net Debt$ -1.71B$ -1.77B$ -1.87B$ -1.46B$ -1.50B
Total Liabilities$ 316.47M$ 358.90M$ 355.08M$ 346.77M$ 359.04M
Stockholders Equity$ 1.94B$ 1.98B$ 2.08B$ 1.88B$ 1.73B
Cash Flow-
Free Cash Flow$ -107.13M$ -96.29M$ 109.03M$ -96.81M$ -41.97M
Operating Cash Flow$ -106.91M$ -95.58M$ 109.75M$ -96.07M$ -39.86M
Investing Cash Flow$ -161.60M$ -126.91M$ -97.80M$ -81.45M$ 121.35M
Financing Cash Flow$ 9.64M$ -466.00K$ 305.93M$ 38.94M$ 1.56M
Currency in USD

Crispr Therapeutics AG Earnings and Revenue History

Crispr Therapeutics AG Debt to Assets

Crispr Therapeutics AG Cash Flow

Crispr Therapeutics AG Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis